The FAITH Trial: Baseline Characteristics of a Church-based Trial to Improve Blood Pressure Control in Blacks. Academic Article uri icon

Overview

abstract

  • OBJECTIVE: To describe the baseline characteristics of participants in the Faith-based Approaches in the Treatment of Hypertension (FAITH) Trial. DESIGN: FAITH evaluates the effectiveness of a faith-based lifestyle intervention vs health education control on blood pressure (BP) reduction among hypertensive Black adults. SETTING PARTICIPANTS AND MAIN MEASURES: Participants included 373 members of 32 Black churches in New York City. Baseline data collected included participant demographic characteristics, clinical measures (eg, blood pressure), behaviors (eg, diet, physical activity), and psychosocial factors (eg, self-efficacy, depressive symptoms). RESULTS: Participants had a mean age of 63.4 ± 11.9 years and 76% were female. About half completed at least some college (53%), 66% had an income ≥$20,000, and 42.2% were retired or on disability. Participants had a mean systolic and diastolic BP of 152.1 ± 16.8 mm Hg and 86.2 ± 12.2 mm Hg, respectively, and a mean BMI of 32 kg/m2. Hypertension (HTN) medications were taken by 95% of participants, but most (79.1%) reported non-adherence to their regimen. Participants reported consuming 3.4 ± 2.6 servings of fruits and vegetables and received 30.9% of their energy from fat. About one-third (35.9%) reported a low activity level. CONCLUSIONS: Participants in the FAITH trial exhibited several adverse clinical and behavioral characteristics at baseline. Future analyses will evaluate the effectiveness of the faith-based lifestyle intervention on changes in BP and lifestyle behaviors among hypertensive Black adults.

publication date

  • August 7, 2015

Research

keywords

  • Black or African American
  • Blood Pressure
  • Feeding Behavior
  • Hypertension
  • Life Style
  • Religion

Identity

PubMed Central ID

  • PMC4671406

Scopus Document Identifier

  • 84962593749

Digital Object Identifier (DOI)

  • 10.18865/ed.25.3.337

PubMed ID

  • 26674992

Additional Document Info

volume

  • 25

issue

  • 3